<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10944552
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     09
    </month>
    <day>
     20
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     09
    </month>
    <day>
     20
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0027-8874
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       92
      </volume>
      <issue>
       16
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Aug
       </month>
       <day>
        16
       </day>
      </pubdate>
     </journalissue>
     <title>
      Journal of the National Cancer Institute
     </title>
     <isoabbreviation>
      J. Natl. Cancer Inst.
     </isoabbreviation>
    </journal>
    <articletitle>
     Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up.
    </articletitle>
    <pagination>
     <medlinepgn>
      1308-16
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      The Mayo Lung Project (MLP) was a randomized, controlled clinical trial of lung cancer screening that was conducted in 9211 male smokers between 1971 and 1983. The intervention arm was offered chest x-ray and sputum cytology every 4 months for 6 years; the usual-care arm was advised at trial entry to receive the same tests annually. No lung cancer mortality benefit was evident at the end of the study. We have extended follow-up through 1996.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      A National Death Index-PLUS search was used to assign vital status and date and cause of death for 6523 participants with unknown information. The median survival for lung cancer patients diagnosed before July 1, 1983, was calculated by use of Kaplan-Meier estimates. Survival curves were compared with the log-rank test.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The median follow-up time was 20.5 years. Lung cancer mortality was 4.4 (95% confidence interval [CI] = 3.9-4.9) deaths per 1000 person-years in the intervention arm and 3.9 (95% CI = 3.5-4.4) in the usual-care arm (two-sided P: for difference =.09). For participants diagnosed with lung cancer before July 1, 1983, survival was better in the intervention arm (two-sided P: =.0039). The median survival for patients with resected early-stage disease was 16.0 years in the intervention arm versus 5.0 years in the usual-care arm.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Extended follow-up of MLP participants did not reveal a lung cancer mortality reduction for the intervention arm. Similar mortality but better survival for individuals in the intervention arm indicates that some lesions with limited clinical relevance may have been identified in the intervention arm.
     </abstracttext>
    </abstract>
    <affiliation>
     Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7354, USA. pm145q@nih.gov
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Marcus
      </lastname>
      <forename>
       P M
      </forename>
      <initials>
       PM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bergstralh
      </lastname>
      <forename>
       E J
      </forename>
      <initials>
       EJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fagerstrom
      </lastname>
      <forename>
       R M
      </forename>
      <initials>
       RM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Williams
      </lastname>
      <forename>
       D E
      </forename>
      <initials>
       DE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fontana
      </lastname>
      <forename>
       R
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Taylor
      </lastname>
      <forename>
       W F
      </forename>
      <initials>
       WF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Prorok
      </lastname>
      <forename>
       P C
      </forename>
      <initials>
       PC
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Controlled Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Natl Cancer Inst
    </medlineta>
    <nlmuniqueid>
     7503089
    </nlmuniqueid>
    <issnlinking>
     0027-8874
    </issnlinking>
   </medlinejournalinfo>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Natl Cancer Inst. 2001 Feb 21;93(4):320-1; author reply 322-3
     </refsource>
     <pmid version="1">
      11181782
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Natl Cancer Inst. 2000 Aug 16;92(16):1292-4
     </refsource>
     <pmid version="1">
      10944548
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Natl Cancer Inst. 2000 Aug 16;92(16):1280-2
     </refsource>
     <pmid version="1">
      10944539
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Natl Cancer Inst. 2001 Feb 21;93(4):321-3
     </refsource>
     <pmid version="1">
      11181783
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Algorithms
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Bias (Epidemiology)
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carcinoma, Non-Small-Cell Lung
     </descriptorname>
     <qualifiername majortopicyn="N">
      mortality
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carcinoma, Small Cell
     </descriptorname>
     <qualifiername majortopicyn="N">
      mortality
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Confounding Factors (Epidemiology)
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lung Neoplasms
     </descriptorname>
     <qualifiername majortopicyn="Y">
      mortality
     </qualifiername>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
     <qualifiername majortopicyn="N">
      surgery
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Mass Screening
     </descriptorname>
     <qualifiername majortopicyn="Y">
      statistics &amp; numerical data
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Survival Analysis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Survival Rate
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      United States
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      8
     </month>
     <day>
      17
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      9
     </month>
     <day>
      23
     </day>
     <hour>
      11
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      8
     </month>
     <day>
      17
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10944552
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

